Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) EPS (Basic) (2016 - 2025)

Amphastar Pharmaceuticals has reported EPS (Basic) over the past 13 years, most recently at $0.53 for Q4 2025.

  • Quarterly results put EPS (Basic) at $0.53 for Q4 2025, down 32.91% from a year ago — trailing twelve months through Dec 2025 was $2.1 (down 36.17% YoY), and the annual figure for FY2025 was $2.1, down 36.17%.
  • EPS (Basic) for Q4 2025 was $0.53 at Amphastar Pharmaceuticals, up from $0.38 in the prior quarter.
  • Over the last five years, EPS (Basic) for AMPH hit a ceiling of $1.01 in Q3 2023 and a floor of $0.11 in Q1 2021.
  • Median EPS (Basic) over the past 5 years was $0.54 (2023), compared with a mean of $0.57.
  • Biggest five-year swings in EPS (Basic): skyrocketed 675.0% in 2021 and later crashed 54.22% in 2025.
  • Amphastar Pharmaceuticals' EPS (Basic) stood at $0.41 in 2021, then surged by 70.73% to $0.7 in 2022, then increased by 7.14% to $0.75 in 2023, then rose by 5.33% to $0.79 in 2024, then plummeted by 32.91% to $0.53 in 2025.
  • The last three reported values for EPS (Basic) were $0.53 (Q4 2025), $0.38 (Q3 2025), and $0.66 (Q2 2025) per Business Quant data.